All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

110

Reset

110 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • Rina-SPRO1184, GEN1184Phase 39 trials

    Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer

  • UtidelonePhase 38 trials

    Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma

  • IBI363Phase 37 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer

  • JSKN003Phase 37 trials

    Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • IpatasertibRO5532961, GDC-0068Phase 35 trials

    Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • SYS6043Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma

  • AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials

    AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • OregovomabMAb-B43.13Phase 34 trials

    CanariaBio Inc. · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Neoplasms

  • ZN-c3azenosertibPhase 34 trials

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma

  • AL2846Phase 33 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer

  • ESG401Phase 33 trials

    Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast

  • H1 receptor antagonistPhase 33 trials

    Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer

  • HS-20089Phase 33 trials

    Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer

  • IBI354Phase 33 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal

  • IMNN-001IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1Phase 33 trials

    Imunon · Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer

  • INCB123667Phase 33 trials

    Incyte · Ovarian Cancer

  • LHRHLuteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone AgonistsPhase 33 trials

    AstraZeneca · ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer

  • Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials

    Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer

  • TaxanePhase 33 trials

    AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer

  • CMP 001VidutolimodPhase 32 trials

    Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer

  • NP-G2-044PrilukaePhase 32 trials

    Novita Pharmaceuticals, Inc. · Platinum-resistant Ovarian Cancer, Advanced or Metastatic Solid Tumor Malignancies

  • PamiparibBGB-290Phase 32 trials

    BeOne Medicines (BeiGene) · Ovarian Cancer, Advanced Malignancies

  • SHR-2004Phase 32 trials

    Beijing Suncadia Pharmaceuticals Co., Ltd · Prevention of Arterial and Venous Thrombosis, Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

  • SHR-A1921Phase 32 trials

    Shanghai Hengrui Pharmaceutical Co., Ltd. · Advanced Solid Tumors, Ovarian Cancer

  • TR115Phase 32 trials

    Tarapeutics Science Inc. · Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent

  • XNW28012Phase 32 trials

    Evopoint Biosciences Inc. · Pancreatic Cancer, Advanced Solid Tumors, Pancreatic Carcinoma

  • arboplatinPhase 31 trial

    Hansoh BioMedical R&D Company · Platinum-sensitive Recurrent Ovarian Cancer

  • IMP4927Phase 31 trial

    Impact Therapeutics, Inc. · Ovarian Cancer

  • PF04518600Phase 31 trial

    Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer

  • UtomilumabPhase 31 trial

    Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer

  • PalacaparibAZD9574Phase 25 trials

    AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • Zelenectide pevedotinBT8009Phase 25 trials

    BicycleTx Limited · Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors

  • MK-2010LM-299Phase 24 trials

    Merck & Co. · Advanced Solid Tumors, Malignant Neoplasm, Malignant Tumors

  • TUB-040Phase 24 trials

    Gilead Sciences · Ovarian Cancer, Non-small Cell Lung Cancer, Uterine Endometrial Cancer

  • UbamatamabREGN4018Phase 24 trials

    Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

  • BT5528nuzefatide pevedotinPhase 23 trials

    BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer

Page 1 of 3Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.